Find your next paid study

National Cancer Institute (NCI)NCT05588128

~$10 – $675

Phase 3

A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus and…

Novartis PharmaceuticalsNCT06855277

Protoacoustic Imaging for 3D Mapping the Bragg Peak in Real Time During Proton Therapy (PROTEUS)

The purpose of this study is to test a new imaging technology called radioacoustic imaging (RAI) that may help doctors see where radiation is being delivered d…

Proton TherapyRadiation Therapy, Secondary Skin ReactionsLiver Cancer+1 more

University of OklahomaNCT07832617

~$10 – $750

High-Risk Localized Prostate Cancer

A Phase II Non-blinded Randomized Study Comparing External Beam Radiotherapy (EBRT), 177Lu-PSMA-617, and Short Term Androgen Deprivation Therapy (ADT) Versus EBRT and Long Term ADT in Men With High Risk Localized Prostate Cancer

This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) trea…

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07550517

Observational

CV CARE: CardioVascular Care of Androgen Related Effects in Prostate Cancer Patients

This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting an…

Prostate CancerCardiovascular Diseases

Dana-Farber Cancer InstituteNCT06202820

~$10 – $7,500

A Prospective Phase 2/3, Multicenter, Open Label Study of [68Ga]- LNTH2401 PET/CT Imaging in Participants With Prostate Cancer: Phase 2 Dose Optimization in Either Newly Diagnosed or Biochemically Recurrent Prostate Cancer and Phase 3 Diagnostic Performance in Participants Who Are Newly Diagnosed and Have at Least High Risk or Suspected Metastatic Disease and Planning to Undergo Radical Prostatectomy Plus Pelvic Lymph Node Dissection (SPARROW)

This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 …

Lantheus Medical ImagingNCT07831824

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Patients With Recurrent Prostate Cancer After Prostatectomy

Purpose: Prospective, single-site Phase II study testing whether PSMA-PET/MRI-guided, de-escalated salvage radiation reduces acute Grade ≥2 toxicity versus a 4…

University of NebraskaNCT07234981

Observational

Exercise-induced Steroid Changes in Active Surveillance for Prostate Cancer

The purpose of this research study is to understand how a short session of a home-based bodyweight high-intensity interval training (HIIT) affects steroid horm…

University of MiamiNCT07518888

Recurrent Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8Castration-Sensitive Prostate Cancer+9 more

A Phase II Randomized Trial of Intermittent Androgen Deprivation Therapy Alone or Combined With [177Lu]Lu-PSMA-617, With or Without Abiraterone and Prednisone, in Patients With Low-Volume Metastatic Hormone-Sensitive Prostate Cancer

This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treat…

Progressive Metastatic Castrate Resistant Prostate Cancer

Mayo ClinicNCT07650240

Phase 1

TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462…

Novartis PharmaceuticalsNCT07206056

Phase 1

A Phase 1 Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SHY-ONC6 in Participants With Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity o…

Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer (TNBC)HR+ Breast Cancer+8 more

SHY TherapeuticsNCT07705334

Phase 3

Alternative Boost Approaches in Radiation Therapy IRreversible Electroporation Versus RADIAtioN BoosT for Intermediate Risk Prostate Cancer (IRRADIANT)

In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the …